Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16669006 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL974237 | 0.71 | ALDH1A1 (0.41) | MAPTL3MBTL1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL5030 | 0.68 | ALDH1A1 (0.54) | AHRKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL28756926 | 0.67 | ALDH1A1 (0.52) | AHRKDM4ESMN1; SMN2ALDH1A1HPGD | |
| Ammonia Solution, Strong SCHEMBL29143440 | 0.67 | ALDH1A1 (0.52) | AHRKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL28379563 | 0.67 | ALDH1A1 (0.52) | AHRKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5497510 | 0.67 | ATM (0.47) | — | |
| SCHEMBL28458247 | 0.67 | ALDH1A1 (0.52) | AHRKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2074995 | 0.67 | AHR (0.47) | AHRMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL135237 | 0.65 | CYP1A2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| CN-101018552-A | Intracellular receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | AHR 1370/4885MAPT 3411/4885NPC1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.